CyFlow™ CD19 APC-Cy7

CyFlow™ CD19 APC-Cy7
Laser: Red
Target Species: Human
Antigen: CD19
Field of Interest: Immunophenotyping
Clone: LT19
Regulatory Status: RUO
Alternative Name: B4
Application: Flow cytometry
Format/Fluorochrome: APC-Cy7
Species of Origin: Mouse
Clonality: monoclonal
Emission Maximum: 780 nm
Excitation Maximum: 650 nm, 750 nm
Isotype: IgG1
Product number: CK907197

For Research Use Only

$295.00 USD*

Price excludes any applicable taxes plus shipping costs

HLDA Workshop HLDA 10 Concentration Quantity 100 tests Volume 0.4 mL... more
CyFlow™ CD19 APC-Cy7
HLDA WorkshopHLDA 10
Concentration
Quantity100 tests
Volume0.4 mL
ImmunogenDaudi human Burkitt lymphoma cell line
Background InformationCD19 is a transmembrane glycoprotein of Ig superfamily expressed by B cells from the time of heavy chain rearrangement until plasma cell differentiation. It forms a tetrameric complex with CD21 (complement receptor type 2), CD81 (TAPA-1) and Leu13. Together with BCR (B cell antigen receptor), this complex signals to decrease B cell treshold for activation by the antigen. Besides being signal-amplifying coreceptor for BCR, CD19 can also signal independently of BCR coligation and it turns out to be a central regulatory component upon which multiple signaling pathways converge. Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.

Specific References

| Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF: CD19 amplifies B lymphocyte signal transduction by regulating Src‑family protein tyrosine kinase activation. J·Immunol. 1999·Jun·15; 162(12):7088‑94. <·PMID:·10358152·> | Inabe K, Kurosaki T: Tyrosine phosphorylation of B‑cell adaptor for phosphoinositide 3‑kinase is required for Akt activation in response to CD19 engagement. Blood. 2002·Jan·15; 99(2):584‑9. <·PMID:·11781242·> | Elias F, Flo J, Lopez RA, Zorzopulos J, Montaner A, Rodriguez JM: Strong cytosine‑guanosine‑independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J·Immunol. 2003·Oct·1; 171(7):3697‑704. <·PMID:·14500668·> | Lin CW, Liu TY, Chen SU, Wang KT, Medeiros LJ, Hsu SM: CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features. Blood. 2005·Nov·15; 106(10):3567‑74. <·PMID:·16046525·> | van Zelm MC, Reisli I, van der Burg M, Castaño D, van Noesel CJ, van Tol MJ, Woellner C, Grimbacher B, Patiño PJ, van Dongen JJ, Franco JL: An antibody‑deficiency syndrome due to mutations in the CD19 gene. N·Engl·J·Med. 2006·May·4; 354(18):1901‑12. <·PMID:·16672701·> | Shi X, Xie C, Chang S, Zhou XJ, Tedder T, Mohan C: CD19 hyperexpression augments Sle1‑induced humoral autoimmunity but not clinical nephritis. Arthritis·Rheum. 2007·Sep; 56(9):3057‑69. <·PMID:·17763445·> | Stehlíková O, Chovancová J, Tichý B, Krejčí M, Brychtová Y, Panovská A, Francová Skuhrová H, Burčková K, Borský M, Loja T, Mayer J, Pospíšilová S, Doubek M: Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8‑color flow cytometry protocol in routine hematological practice. Int·J·Lab·Hematol. 2014·Apr; 36(2):165‑71. <·PMID:·24028768·>

Article successfully added.